Almirall, S.A.: Almirall's Nine-month 2022 Results

Almirall achieves core net sales of €633.8 MM Euros in the first nine months of 2022 showing a solid 5.3% growth Almirall continues solid business momentum in Q3 with an acceleration of sales

Related Keywords

Germany ,Norway ,Taiwan ,Hong Kong ,United Kingdom ,China ,Portugal ,Czech Republic ,Austria ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Netherlands ,Denmark ,Italy ,Sweden ,Finland ,Ireland ,France ,Macau ,Spanish ,German ,Crutchleyn Polyaphron ,Carlos Gallardo ,Gianfranco Nazzi ,Omar Ram ,Astrazeneca Covis ,Las Vegas ,Betamethasone Dipropionate ,European Academy Of Dermatology ,Simcere Pharmaceutical Group For ,European Association Of Dermatology ,Astrazeneca ,Corporate Communications ,European Medicines Agency ,Venereology Congress Almirall ,Wynn Hotel ,Congress Almirall ,Spanish Stock Exchange ,European Dermatology ,Marketing Authorization Application ,Deferred Income ,Core Net Sales ,Net Sales ,Net Debt ,European Association ,Annual Fall Clinical Dermatology Conference ,Pharma Trend Image Innovation ,Oral Antibiotics ,European Academy ,Reference Member ,Simcere Pharmaceutical Group ,Greater China ,Mainland China ,Medical Dermatology ,Ichnos Science ,Results February ,Noble Purpose ,Dermatology Therapy ,Clinical Dermatology ,United States ,Moderate To Severe Atopic Dermatitis ,Week Results ,Two Randomized ,Placebo Controlled Phase ,Divasson Del Fraile ,Almirall ,Line ,Month ,022 ,Results ,